What's hot
View all perspectives
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
On now: The Great Debate - is MCTD a distinct clinical entity?
@DrLisaCS reviews the history of MCTD classification criteria and its evolution
Kasukawa criteria may be most sensitive in one cohort
@RheumNow #ACR24 https://t.co/rDHafZVL1I
Antoni Chan MD (Prof) synovialjoints
9 months 3 weeks ago
A study showed the sex differences in serum proteomic profiles of males and females with PsA.
Key findings:
-Identified 741 unique proteins in male PsA patients vs. controls vs. 31 in females.
- Several sex-specific pathways, including immune cell functions and cytokine… https://t.co/erC599Zbuj
Richard Conway RichardPAConway
9 months 3 weeks ago
Chinoy et al. Baricitinib in IIM. Delayed-start clinical trial. 15 patients. 14/15 improved at 24 weeks (the other withdrew). 50% vs 100% at week 12 (delayed start group initiation). Stats confuse me a bit here but promising. @RheumNow #ACR24 Abstr#1731 https://t.co/orewsxbPpL https://t.co/5AyRpYJdec
Eric Dein ericdeinmd
9 months 3 weeks ago
A#1746 companion for RA
Like plenary for PsA, PBO response incr w time 1%/yr
More trials in less affluent countries may be related to increasing PBO response in trials
Possible reason: access to health care improves PBO in less affluent areas
@RheumNow #ACR24 https://t.co/S3LffF8vPH
Jiha Lee JihaRheum
9 months 3 weeks ago
RA patients on TOF with h/o ASCVD have 4x higher risk of MACE without statin (vs. TNFi).
Prioritize statins for heart health in RA!
#ACR24 @RheumNow ABST#1745 https://t.co/jRqXNU2T6d
sheila RHEUMarampa
9 months 3 weeks ago
The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al.
axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed
@RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x
Eric Dein ericdeinmd
9 months 3 weeks ago
A#1745
Post-hoc ORAL Surveillance - statin
<1/4 on a statin, only 53% h/o ASCVD on statin
Incr in LDL was less on Tofa pts on statin
Among those on b/l statins, there is no incr risk compare to TNFi, esp pts h/o ASCVD
If high risk on tofa, statin helps!
@RheumNow #ACR24 #ACRBest https://t.co/7MGgUk7tfI
Richard Conway RichardPAConway
9 months 3 weeks ago
Wallace et al. Case control study. 648 cases 1241 controls. Cumulative glucocorticoid dose and risk MACE. Dose dependent increase in risk, OR 1.01 for 10% increase GC, 1.21 for 10-fold increase GC. @RheumNow #ACR24 Abstr#1719 https://t.co/wraiWOl1dv https://t.co/feht58RDNc
Antoni Chan MD (Prof) synovialjoints
9 months 3 weeks ago
Single cell TCR sequence study explores the limitations of TRBV9-depleting therapies in axial spondyloarthritis.
Key findings:
- Identified a clonally expanded TRBV5-5+ TCR in HLA-B27+ acute anterior uveitis.
- Alternative TRBVs may retain pathogenicity and evade anti-TRBV9… https://t.co/Aj8oslsTNX
Adela Castro AdelaCastro222
9 months 3 weeks ago
📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved
substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52.
-PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52.
Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9
Eric Dein ericdeinmd
9 months 3 weeks ago
A#1744 AI for RA to improve scheduling in UK
39% pts meet quality metric for early intervention
Input: RF, CRP, CCP, gender, age -> 51% accuracy (compare to first appt clinical accur 46%)
Focusing on highest risk -> 88% accuracy -> 50% wait time for high-risk pts
#ACR24 @RheumNow
Jiha Lee JihaRheum
9 months 3 weeks ago
Strive for remission (CDAI ≤2.8) to achieve better functional outcomes in RA
#ACR24 @RheumNow ABST#1743 https://t.co/qpsTF54rmW
Adela Castro AdelaCastro222
9 months 3 weeks ago
In a cohort of >17,000 European pts w/ axSpA:
-bDMARD naïve pts starting TNFi or IL-17Ai were more likely to achieve LDA than TNF-experienced.
-Higher time to achieve LDA and shorter durability in pts with prior TNFi use.
Abst#1756 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey
9 months 3 weeks ago
Further evidence for risk of #MACE with cumulative GC use in RA
In a national cohort of pts with RA: ⬆️cumulative GC exposure associated with ⬆️odds of MACE, regardless of baseline MACE risk
Ab1719 #ACR24 @RheumNow https://t.co/RmxokfBXYX
Antoni Chan MD (Prof) synovialjoints
9 months 3 weeks ago
Study revealing the Uterine-Joint Axis in female axial spondyloarthritis, highlighting dysbiosis and subclinical uterine inflammation as key factors in disease pathogenesis.
Key findings:
- Distinct microbiota profiles in AxSpA patients vs. healthy controls.
- Significant genital… https://t.co/Cl12ELdjI2
Poster Hall